Best responses according to histology (all doses, ITT population)
| Histology . | Response, n/N (%) . | Median (95% CI) DOR,* mo . | ||||
|---|---|---|---|---|---|---|
| ORR . | CR . | PR . | Stable disease . | PD . | ||
| All patients | 32/69 (46) | 12/69 (17) | 20/69 (29) | 18/69 (26) | 19/69 (28) | 20.2 (11.3-NR) |
| CLL/SLL | 13/21 (62) | 2/21 (10) | 11/21 (52) | 5/21 (24) | 3/21 (14) | 25.9 (5.0-NR) |
| 17p deletion | 4/8 (50) | 1/8 (13) | 3/8 (38) | 3/8 (38) | 1/8 (13) | — |
| Aggressive B-NHL | 6/25 (24) | 3/25 (12) | 3/25 (12) | 6/25 (24) | 13/25 (52) | — |
| DLBCL | 5/22 (23) | 3/22 (14) | 2/22 (9) | 6/22 (27) | 11/22 (50) | 15.6 (5.6-NR) |
| GCB | 3/12 (25) | 2/12 (17) | 1/12 (8) | 3/12 (25) | 6/12 (50) | — |
| Non-GCB | 1/4 (25) | 0/4 (0) | 1/4 (25) | 1/4 (25) | 2/4 (50) | — |
| Unknown | 1/6 (17) | 1/6 (17) | 0/6 (0) | 2/6 (33) | 3/6 (50) | — |
| MCL | 0/2 (0) | — | — | — | 2/2 (100) | — |
| RT | 1/1 (100) | — | 1/1 (100) | — | — | 2 |
| Indolent B-NHL | 13/23 (57) | 7/23 (30) | 6/23 (26) | 7/23 (30) | 3/23 (13) | — |
| FL | 8/18 (44) | 4/18 (22) | 4/18 (22) | 7/18 (39) | 3/18 (17) | 20.3 (1.7-NR) |
| MZL | 5/5 (100) | 3/5 (60) | 2/5 (40) | — | — | NR (3.1-NR) |
| Histology . | Response, n/N (%) . | Median (95% CI) DOR,* mo . | ||||
|---|---|---|---|---|---|---|
| ORR . | CR . | PR . | Stable disease . | PD . | ||
| All patients | 32/69 (46) | 12/69 (17) | 20/69 (29) | 18/69 (26) | 19/69 (28) | 20.2 (11.3-NR) |
| CLL/SLL | 13/21 (62) | 2/21 (10) | 11/21 (52) | 5/21 (24) | 3/21 (14) | 25.9 (5.0-NR) |
| 17p deletion | 4/8 (50) | 1/8 (13) | 3/8 (38) | 3/8 (38) | 1/8 (13) | — |
| Aggressive B-NHL | 6/25 (24) | 3/25 (12) | 3/25 (12) | 6/25 (24) | 13/25 (52) | — |
| DLBCL | 5/22 (23) | 3/22 (14) | 2/22 (9) | 6/22 (27) | 11/22 (50) | 15.6 (5.6-NR) |
| GCB | 3/12 (25) | 2/12 (17) | 1/12 (8) | 3/12 (25) | 6/12 (50) | — |
| Non-GCB | 1/4 (25) | 0/4 (0) | 1/4 (25) | 1/4 (25) | 2/4 (50) | — |
| Unknown | 1/6 (17) | 1/6 (17) | 0/6 (0) | 2/6 (33) | 3/6 (50) | — |
| MCL | 0/2 (0) | — | — | — | 2/2 (100) | — |
| RT | 1/1 (100) | — | 1/1 (100) | — | — | 2 |
| Indolent B-NHL | 13/23 (57) | 7/23 (30) | 6/23 (26) | 7/23 (30) | 3/23 (13) | — |
| FL | 8/18 (44) | 4/18 (22) | 4/18 (22) | 7/18 (39) | 3/18 (17) | 20.3 (1.7-NR) |
| MZL | 5/5 (100) | 3/5 (60) | 2/5 (40) | — | — | NR (3.1-NR) |
ITT, intention-to-treat PD, progressive disease.
Calculated for patients who achieved PR or CR.